3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
10
Paclitaxel
7
Iodine-131
6
Fluorodeoxyglucose F18
6
Sorafenib
5
vandetanib
4
trametinib
4
selpercatinib
4
dabrafenib
4
pembrolizumab
3
fosbretabulin
3
cabozantinib
3
Vemurafenib
3
Sunitinib
3
Specimen Handling
3
Nivolumab
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
tipifarnib
2
romidepsin
2
pazopanib
2
lenvatinib
2
combretastatin
2
Trastuzumab
2
Thyrotropin Alfa
2
Ipilimumab
2
Gefitinib
2
FAPI-46
2
Everolimus
2
Doxorubicin
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Clinical Trials, Phase II as Topic
×
Endocrine
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled